guest ::
| Home > Temporary Entries > Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer. > print |
| Home > Temporary Entries > Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer. > print |
| 001 | 286251 | ||
| 005 | 20231218123224.0 | ||
| 024 | 7 | _ | |a 10.3389/fonc.2023.1223915 |2 doi |
| 024 | 7 | _ | |a pmid:37746286 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC10516605 |2 pmc |
| 037 | _ | _ | |a DKFZ-2023-02742 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Song, Yurong |b 0 |
| 245 | _ | _ | |a Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer. |
| 260 | _ | _ | |a Lausanne |c 2023 |b Frontiers Media |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1702898729_31405 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Genome integrity is essential for the survival of an organism. DNA mismatch repair (MMR) genes (e.g., MLH1, MSH2, MSH6, and PMS2) play a critical role in the DNA damage response pathway for genome integrity maintenance. Germline mutations of MMR genes can lead to Lynch syndrome or constitutional mismatch repair deficiency syndrome, resulting in an increased lifetime risk of developing cancer characterized by high microsatellite instability (MSI-H) and high mutation burden. Although immunotherapy has been approved for MMR-deficient (MMRd) cancer patients, the overall response rate needs to be improved and other management options are needed.To better understand the biology of MMRd cancers, elucidate the resistance mechanisms to immune modulation, and develop vaccines and therapeutic testing platforms for this high-risk population, we generated organoids and an orthotopic mouse model from intestine tumors developed in a Msh2-deficient mouse model, and followed with a detailed characterization.The organoids were shown to be of epithelial origin with stem cell features, to have a high frameshift mutation frequency with MSI-H and chromosome instability, and intra- and inter-tumor heterogeneity. An orthotopic model using intra-cecal implantation of tumor fragments derived from organoids showed progressive tumor growth, resulting in the development of adenocarcinomas mixed with mucinous features and distant metastasis in liver and lymph node.The established organoids with characteristics of MSI-H cancers can be used to study MMRd cancer biology. The orthotopic model, with its distant metastasis and expressing frameshift peptides, is suitable for evaluating the efficacy of neoantigen-based vaccines or anticancer drugs in combination with other therapies. |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Lynch syndrome |2 Other |
| 650 | _ | 7 | |a MSH2 |2 Other |
| 650 | _ | 7 | |a chromosome instability |2 Other |
| 650 | _ | 7 | |a colorectal cancer |2 Other |
| 650 | _ | 7 | |a microsatellite instability |2 Other |
| 650 | _ | 7 | |a mismatch repair deficiency |2 Other |
| 650 | _ | 7 | |a mouse model |2 Other |
| 650 | _ | 7 | |a organoid |2 Other |
| 700 | 1 | _ | |a Kerr, Travis D |b 1 |
| 700 | 1 | _ | |a Sanders, Chelsea |b 2 |
| 700 | 1 | _ | |a Dai, Lisheng |b 3 |
| 700 | 1 | _ | |a Baxter, Shaneen S |b 4 |
| 700 | 1 | _ | |a Somerville, Brandon |b 5 |
| 700 | 1 | _ | |a Baugher, Ryan N |b 6 |
| 700 | 1 | _ | |a Mellott, Stephanie D |b 7 |
| 700 | 1 | _ | |a Young, Todd B |b 8 |
| 700 | 1 | _ | |a Lawhorn, Heidi E |b 9 |
| 700 | 1 | _ | |a Plona, Teri M |b 10 |
| 700 | 1 | _ | |a Xu, Bingfang |b 11 |
| 700 | 1 | _ | |a Wei, Lei |b 12 |
| 700 | 1 | _ | |a Hu, Qiang |b 13 |
| 700 | 1 | _ | |a Liu, Song |b 14 |
| 700 | 1 | _ | |a Hutson, Alan |b 15 |
| 700 | 1 | _ | |a Karim, Baktiar |b 16 |
| 700 | 1 | _ | |a Burkett, Sandra |b 17 |
| 700 | 1 | _ | |a Difilippantonio, Simone |b 18 |
| 700 | 1 | _ | |a Pinto, Ligia |b 19 |
| 700 | 1 | _ | |a Gebert, Johannes |b 20 |
| 700 | 1 | _ | |a Kloor, Matthias |b 21 |
| 700 | 1 | _ | |a Lipkin, Steven M |b 22 |
| 700 | 1 | _ | |a Sei, Shizuko |b 23 |
| 700 | 1 | _ | |a Shoemaker, Robert H |b 24 |
| 773 | _ | _ | |a 10.3389/fonc.2023.1223915 |g Vol. 13, p. 1223915 |0 PERI:(DE-600)2649216-7 |p 1223915 |t Frontiers in oncology |v 13 |y 2023 |x 2234-943X |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT ONCOL : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-05-11T13:25:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-05-11T13:25:45Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2021-05-11T13:25:45Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-11T13:25:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-26 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-26 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-26 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-26 |
| 920 | 2 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a TEMPENTRY |
| 980 | _ | _ | |a VDBRELEVANT |
| 980 | _ | _ | |a I:(DE-He78)F210-20160331 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|